Chemotherapy targeted to cancers through tumoral hormone receptors (Q35879365)

scientific article published in September 2004

Language	Label	Description	Also known as
English	Chemotherapy targeted to cancers through tumoral hormone receptors	scientific article published in September 2004

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

title

Chemotherapy targeted to cancers through tumoral hormone receptors (English)

1 reference

stated in

Europe PubMed Central

10 August 2017

1 reference

1

Andrew V Schally

1 reference

stated in

Europe PubMed Central

10 August 2017

Attila Nagy

2

1 reference

stated in

Europe PubMed Central

10 August 2017

1 September 2004

1 reference

stated in

Europe PubMed Central

10 August 2017

Trends in Endocrinology and Metabolism

1 reference

stated in

Europe PubMed Central

10 August 2017

15

1 reference

stated in

Europe PubMed Central

10 August 2017

7

1 reference

stated in

Europe PubMed Central

10 August 2017

300-310

1 reference

stated in

Europe PubMed Central

10 August 2017

Drug-targeting strategies in cancer therapy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Somatostatin analogs in the diagnosis and treatment of cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Therapeutic cancer targeting peptides

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Peptide receptors as molecular targets for cancer diagnosis and therapy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Targeted toxin therapy for the treatment of cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Hypothalamic hormones and cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Somatostatin, its receptors and analogs, in lung cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Somatostatin and its receptor family

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Human ovarian cancers express somatostatin receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.TEM.2004.07.002

Identifiers

DOI

10.1016/J.TEM.2004.07.002

1 reference

stated in

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

PubMed ID

15350601

retrieved

10 August 2017

Chemotherapy targeted to cancers through tumoral hormone receptors (Q35879365)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Chemotherapy targeted to cancers through tumoral hormone receptors (Q35879365)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search